Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 476

1.

Gastrectomy case volume and textbook outcome: an analysis of the Population Registry of Esophageal and Stomach Tumours of Ontario (PRESTO).

Levy J, Gupta V, Amirazodi E, Allen-Ayodabo C, Jivraj N, Jeong Y, Davis LE, Mahar AL, De Mestral C, Saarela O, Coburn N; PRESTO Group.

Gastric Cancer. 2019 Nov 4. doi: 10.1007/s10120-019-01015-w. [Epub ahead of print]

PMID:
31686260
2.

Stage at diagnosis and survival in patients with cancer and a pre-existing mental illness: a meta-analysis.

Davis LE, Bogner E, Coburn NG, Hanna TP, Kurdyak P, Groome PA PhD, Mahar AL.

J Epidemiol Community Health. 2019 Oct 25. pii: jech-2019-212311. doi: 10.1136/jech-2019-212311. [Epub ahead of print] Review.

PMID:
31653661
3.

Population-based study of the prevalence and management of self-reported high pain scores in patients with non-resected pancreatic adenocarcinoma.

Tung S, Coburn NG, Davis LE, Mahar AL, Myrehaug S, Zhao H, Earle CC, Nathens A, Hallet J.

Br J Surg. 2019 Nov;106(12):1666-1675. doi: 10.1002/bjs.11330.

PMID:
31639208
4.

Symptom burden among head and neck cancer patients in the first year after diagnosis: Association with primary treatment modality.

Allen-Ayodabo CO, Eskander A, Davis LE, Zhao H, Mahar AL, Karam I, Singh S, Gupta V, Bubis LD, Moody L, Barbera L, Coburn NG.

Oral Oncol. 2019 Oct 17;99:104434. doi: 10.1016/j.oraloncology.2019.09.026. [Epub ahead of print]

PMID:
31630058
5.

Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis.

Hallet J, Davis LE, Mahar AL, Liu Y, Zuk V, Gupta V, Earle CC, Coburn NG.

Gastric Cancer. 2019 Oct 18. doi: 10.1007/s10120-019-01012-z. [Epub ahead of print]

PMID:
31628561
6.

Development of a tool to assess and advance the effectiveness of preceptors: The Habits of Preceptors Rubric.

Larson S, Davis LE, Stevens AM, El-Ibiary S, Grice G, Pogge E, Raney E, Storjohann T.

Am J Health Syst Pharm. 2019 Oct 15;76(21):1762-1769. doi: 10.1093/ajhp/zxz183.

PMID:
31612921
7.

Authors' Reply to the Response to "Patient-reported symptom severity among 22,650 cancer outpatients in the last 6 months of life".

Bubis LD, Davis LE, Coburn NG, Mahar AL.

J Pain Symptom Manage. 2019 Oct 11. pii: S0885-3924(19)30572-X. doi: 10.1016/j.jpainsymman.2019.09.023. [Epub ahead of print] No abstract available.

PMID:
31610270
8.

Recent advances in therapies for eating disorders.

Davis LE, Attia E.

F1000Res. 2019 Sep 26;8. pii: F1000 Faculty Rev-1693. doi: 10.12688/f1000research.19847.1. eCollection 2019. Review.

9.

Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.

Lu E, Ryan CW, Bassale S, Lim JY, Davis LE.

Oncologist. 2019 Oct 2. pii: theoncologist.2019-0532. doi: 10.1634/theoncologist.2019-0532. [Epub ahead of print]

PMID:
31578275
10.

Comparison of Patient-Reported Outcomes in Laparoscopic and Open Right Hemicolectomy: A Retrospective Cohort Study.

Vela N, Bubis LD, Davis LE, Mahar AL, Kennedy E, Coburn NG.

Dis Colon Rectum. 2019 Sep 20. doi: 10.1097/DCR.0000000000001485. [Epub ahead of print]

PMID:
31567922
11.

Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer.

Vela N, Davis LE, Cheng SY, Hammad A, Liu Y, Kagedan DJ, Paszat L, Bubis LD, Earle CC, Myrehaug S, Mahar AL, Mittmann N, Coburn NG; Pancreas Cancer Population Outcomes Research Group.

Ann Surg Oncol. 2019 Sep 18. doi: 10.1245/s10434-019-07808-8. [Epub ahead of print]

PMID:
31535303
12.

Histone Modifications as Biomarkers for Immunotherapy.

Taylor EM, Koss B, Davis LE, Tackett AJ.

Methods Mol Biol. 2020;2055:213-228. doi: 10.1007/978-1-4939-9773-2_10.

PMID:
31502154
13.

Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma.

Tung S, Davis LE, Hallet J, Mavros MN, Mahar AL, Bubis LD, Hammad A, Zhao H, Earle CC, Barbera L, Coburn NG; and the Pancreas Cancer Population Outcomes Research Group, Siqqidui M, Li Q, Elmi M, Shin E, Hsieh E, Goyert N.

JAMA Surg. 2019 Sep 4:e193348. doi: 10.1001/jamasurg.2019.3348. [Epub ahead of print]

PMID:
31483457
14.

Effect of Intermittent Versus Continuous Low-Dose Aspirin on Nasal Epithelium Gene Expression in Current Smokers: A Randomized, Double-Blinded Trial.

Garland LL, Guillen-Rodriguez J, Hsu CH, Yozwiak M, Zhang HH, Alberts DS, Davis LE, Szabo E, Merenstein C, Lel J, Zhang X, Liu H, Liu G, Spira AE, Beane JE, Wojtowicz M, Chow HS.

Cancer Prev Res (Phila). 2019 Nov;12(11):809-820. doi: 10.1158/1940-6207.CAPR-19-0036. Epub 2019 Aug 26.

PMID:
31451521
15.

Patient-reported symptom severity among 22,650 cancer outpatients in the last 6 months of life.

Bubis LD, Davis LE, Canaj H, Gupta V, Jeong Y, Barbera L, Li Q, Moody L, Karanicolas PJ, Sutradhar R, Coburn NG, Mahar AL.

J Pain Symptom Manage. 2019 Aug 17. pii: S0885-3924(19)30462-2. doi: 10.1016/j.jpainsymman.2019.08.016. [Epub ahead of print]

PMID:
31430522
16.

PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor.

Davis LE, Nicholls LA, Babiker HM, Liau J, Mahadevan D.

Cancer Immunol Res. 2019 Sep;7(9):1396-1400. doi: 10.1158/2326-6066.CIR-19-0072. Epub 2019 Aug 5.

PMID:
31383651
17.

Current state of melanoma diagnosis and treatment.

Davis LE, Shalin SC, Tackett AJ.

Cancer Biol Ther. 2019;20(11):1366-1379. doi: 10.1080/15384047.2019.1640032. Epub 2019 Aug 1.

18.

Symptom trajectories and predictors of severe symptoms in pancreatic adenocarcinoma at the end-of-life: a population based analysis of 2,538 patients.

Hammad A, Davis LE, Mahar AL, Bubis LD, Zhao H, Earle CC, Barbera L, Hallet J, Coburn NG.

HPB (Oxford). 2019 Jul 9. pii: S1365-182X(19)30537-4. doi: 10.1016/j.hpb.2019.04.016. [Epub ahead of print]

PMID:
31300337
19.

Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes.

Hallet J, Davis LE, Mahar AL, Law CHL, Isenberg-Grzeda E, Bubis LD, Singh S, Myrehaug S, Zhao H, Beyfuss K, Moody L, Coburn NG.

Oncologist. 2019 Oct;24(10):1384-1394. doi: 10.1634/theoncologist.2019-0112. Epub 2019 Jul 3.

PMID:
31270268
20.

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.

Berlow NE, Rikhi R, Geltzeiler M, Abraham J, Svalina MN, Davis LE, Wise E, Mancini M, Noujaim J, Mansoor A, Quist MJ, Matlock KL, Goros MW, Hernandez BS, Doung YC, Thway K, Tsukahara T, Nishio J, Huang ET, Airhart S, Bult CJ, Gandour-Edwards R, Maki RG, Jones RL, Michalek JE, Milovancev M, Ghosh S, Pal R, Keller C.

BMC Cancer. 2019 Jun 17;19(1):593. doi: 10.1186/s12885-019-5681-6.

21.

Leg Length Discrepancy: The Natural History (And What Do We Really Know).

Gordon JE, Davis LE.

J Pediatr Orthop. 2019 Jul;39(Issue 6, Supplement 1 Suppl 1):S10-S13. doi: 10.1097/BPO.0000000000001396. Review.

PMID:
31169640
22.

Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes.

Hallet J, Davis LE, Mahar AL, Isenberg-Grzeda E, Bubis LD, Myrehaug S, Zhao H, Beyfuss K, Moody L, Law CHL, Coburn NG.

Ann Surg Oncol. 2019 Sep;26(9):2711-2721. doi: 10.1245/s10434-019-07441-5. Epub 2019 May 30.

PMID:
31147993
23.

Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis.

Mavros MN, Coburn NG, Davis LE, Mahar AL, Liu Y, Beyfuss K, Myrehaug S, Earle CC, Hallet J.

CMAJ. 2019 May 27;191(21):E574-E580. doi: 10.1503/cmaj.190211.

24.

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG.

J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23.

PMID:
31013172
25.

Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.

Davis LE, Fulton C, Bubis LD, Sussman J, Moody L, Barbera L, Li Q, Mahar AL, Coburn NG, Holloway CMB.

Breast Cancer Res Treat. 2019 Jun;175(3):721-731. doi: 10.1007/s10549-019-05196-x. Epub 2019 Mar 16.

PMID:
30879223
26.

Factors associated with receipt of symptom screening in the year after cancer diagnosis in a universal health care system: a retrospective cohort study.

Mahar AL, Davis LE, Bubis LD, Li Q, Sutradhar R, Coburn NG, Barbera L.

Curr Oncol. 2019 Feb;26(1):e8-e16. doi: 10.3747/co.26.4160. Epub 2019 Feb 1.

27.

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.

Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, Onorati A, Kalavacharla A, Kim T, Zhen CJ, Kadri S, Segal JP, Gimotty PA, Davis LE, Amaravadi RK.

Clin Cancer Res. 2019 Apr 1;25(7):2080-2087. doi: 10.1158/1078-0432.CCR-18-2204. Epub 2019 Jan 11.

PMID:
30635337
28.

Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.

Wippel B, Gundle KR, Dang T, Paxton J, Bubalo J, Stork L, Fu R, Ryan CW, Davis LE.

Cancer Med. 2019 Jan;8(1):111-116. doi: 10.1002/cam4.1898. Epub 2018 Dec 22.

29.

Foramen ovale blood flow and cardiac function after main pulmonary artery occlusion in fetal sheep.

Lantto J, Erkinaro T, Haapsamo M, Huhta H, Voipio HM, Hohimer AR, Davis LE, Acharya G, Räsänen J.

Exp Physiol. 2019 Feb;104(2):189-198. doi: 10.1113/EP087423. Epub 2019 Jan 13.

PMID:
30578690
30.

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.

Davis LE, Nusser KD, Przybyl J, Pittsenbarger J, Hofmann NE, Varma S, Vennam S, Debiec-Rychter M, van de Rijn M, Davare MA.

Mol Cancer Res. 2019 Mar;17(3):676-685. doi: 10.1158/1541-7786.MCR-18-1075. Epub 2018 Dec 5. Erratum in: Mol Cancer Res. 2019 Sep;17(9):1958.

PMID:
30518629
31.

Dynamin Is Required for Efficient Cytomegalovirus Maturation and Envelopment.

Hasan MH, Davis LE, Bollavarapu RK, Mitra D, Parmar R, Tandon R.

J Virol. 2018 Nov 27;92(24). pii: e01418-18. doi: 10.1128/JVI.01418-18. Print 2018 Dec 15.

32.

Acute Bacterial Meningitis.

Davis LE.

Continuum (Minneap Minn). 2018 Oct;24(5, Neuroinfectious Disease):1264-1283. doi: 10.1212/CON.0000000000000660. Review.

PMID:
30273239
33.
34.

Using Teleneurology to Deliver Chronic Neurologic Care to Rural Veterans: Analysis of the First 1,100 Patient Visits.

Davis LE, Harnar J, LaChey-Barbee LA, Pirio Richardson S, Fraser A, King MK.

Telemed J E Health. 2019 Apr;25(4):274-278. doi: 10.1089/tmj.2018.0067. Epub 2018 Jul 17.

PMID:
30016207
35.

Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study.

Davis LE, Bubis LD, Mahar AL, Li Q, Sussman J, Moody L, Barbera L, Holloway CM, Coburn NG.

Eur J Cancer. 2018 Sep;101:1-11. doi: 10.1016/j.ejca.2018.06.006. Epub 2018 Jul 13.

PMID:
30014970
36.

Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment.

Vander Jagt TA, Davis LE, Thakur MD, Franz C, Pollock JM.

Radiol Case Rep. 2018 Jul 3;13(4):882-885. doi: 10.1016/j.radcr.2018.05.013. eCollection 2018 Aug.

37.

Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.

Lu BN, Davis LE.

JAAPA. 2018 Jul;31(7):35-37. doi: 10.1097/01.JAA.0000534982.53989.c2.

PMID:
29957605
38.

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A.

Cancer Cell. 2018 Jul 9;34(1):9-20. doi: 10.1016/j.ccell.2018.03.023. Epub 2018 May 3. Review.

39.

A Pilot Study on an Interprofessional Course Involving Pharmacy and Dental Students in a Dental Clinic.

Pogge EK, Hunt RJ, Patton LR, Reynolds SC, Davis LE, Storjohann TD, Tennant SE, Call SR.

Am J Pharm Educ. 2018 Apr;82(3):6361. doi: 10.5688/ajpe6361.

40.

A Case of Self-Enucleation in an Incarcerated Patient: Case Report and Review of Literature.

Davis LE, Tripathi S.

J Forensic Sci. 2018 Nov;63(6):1908-1910. doi: 10.1111/1556-4029.13764. Epub 2018 Feb 21. Review.

PMID:
29464687
41.

Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.

Pogge EK, Davis LE.

Am J Cardiovasc Drugs. 2018 Apr;18(2):143-151. doi: 10.1007/s40256-018-0264-5.

PMID:
29455335
42.

Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas.

Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, Ryan CW.

Ann Surg Oncol. 2018 Apr;25(4):920-927. doi: 10.1245/s10434-018-6346-4. Epub 2018 Jan 31.

PMID:
29388122
43.

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?

Fairman KA, Davis LE, Peckham AM, Sclar DA.

Drugs Real World Outcomes. 2018 Mar;5(1):69-79. doi: 10.1007/s40801-017-0129-2.

44.

The Diuretic Potential of Sacubitril/Valsartan: A Tale of 2 Patients.

Hormann SM, Davis LE, Pogge EK.

J Cardiovasc Nurs. 2018 Mar/Apr;33(2):104-110. doi: 10.1097/JCN.0000000000000451.

PMID:
29232274
45.

Osteosarcoma, Chondrosarcoma, and Chordoma.

Whelan JS, Davis LE.

J Clin Oncol. 2018 Jan 10;36(2):188-193. doi: 10.1200/JCO.2017.75.1743. Epub 2017 Dec 8. Review.

PMID:
29220289
46.

Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species.

Davis LE, Jeng S, Svalina MN, Huang E, Pittsenbarger J, Cantor EL, Berlow N, Seguin B, Mansoor A, McWeeney SK, Keller C.

Oncotarget. 2017 Jul 25;8(44):76241-76256. doi: 10.18632/oncotarget.19532. eCollection 2017 Sep 29.

47.

Fetal sheep central haemodynamics and cardiac function during occlusion of the ascending aorta.

Huhta H, Junno J, Haapsamo M, Erkinaro T, Ohtonen P, Davis LE, Hohimer AR, Acharya G, Rasanen J.

Exp Physiol. 2018 Jan 1;103(1):58-67. doi: 10.1113/EP086500. Epub 2017 Dec 3.

PMID:
29094424
48.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Erratum in: Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
49.

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.

Fairman KA, Davis LE, Sclar DA.

Ther Clin Risk Manag. 2017 Aug 3;13:957-965. doi: 10.2147/TCRM.S143008. eCollection 2017.

50.

Clinical trial enrollment of adolescents and young adults with sarcoma.

Davis LE, Janeway KA, Weiss AR, Chen YE, Scharschmidt TJ, Krailo M, Glade Bender JL, Kopp LM, Patel SR, Schwartz GK, Horvath LE, Hawkins DS, Chuk MK, Reinke DK, Gorlick RG, Randall RL.

Cancer. 2017 Sep 15;123(18):3434-3440. doi: 10.1002/cncr.30757. Epub 2017 May 11. Review.

Supplemental Content

Loading ...
Support Center